2014年4月15日

Kineta宣布入學的第一主題1 b臨床試驗”的願景Kineta RLB是進步的臨床發展向地區希望改善獲得重要的新地區醫學治療的病人沒有適當的治療方案,”麗迪雅Bartoszek說管理合夥人兼聯合創始人RLB控股。RLB控股是一家投資公司,旨在揭示有價值的機會,提供社區利益和出穩定增長的態勢。目前這些投資包括一係列不同的公司包括Kineta股權,簡單的願望,和紐約洋基隊。“這種合作結合資源RLB控股與Kineta平移和臨床發展的專業開發新型藥物的候選人,解決迫切的醫療需求,”查爾斯·格尼斯說Kineta的總裁兼首席執行官。誰擔任總裁克雷格·w·飛利浦Kineta RLB,補充說,“這種方法將使我們能夠擴大的一些關鍵資產的生命周期管理Kineta組合和增加我們的發展項目的價值病人和投資者的利益。我們最初的重點將是自身免疫性疾病,一個區域隻有增量盡管巨大的進步需要成千上萬的兒童和成人在美國和海外。“關於RLB控股RLB控股是一家投資公司,成立於2011年由射線和麗迪雅Bartoszek誰帶領公司管理合夥人。RLB奉行多元化投資戰略變革在領先行業的產品和服務。RLB控股旨在揭示有價值的機會將大幅增長,也對也提供積極的經濟和社會效益。選擇投資包括:紐約洋基隊,Solutionpoint國際馬頭砂&轉運碼頭,緊縮健身房,簡單的祝福和Kineta。更多的信息可在www.RLB-Holdings.com獲得。 About Kineta Kineta, Inc. is a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading-edge scientific research. Our world-class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones. For more information on Kineta, Inc. visit our website, www.Kinetabio.com . NOTICE: This press release contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, anticipated drug effects in human subjects, regulatory submissions and financial performance. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation: progress of drug development; intellectual property protection and enforcement; efficacy, and demand for our products; clinical testing and regulatory approval; changes in legislative, fiscal, and other regulatory measures; and our ability to recruit and retain scientists and other key personnel. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. Kineta, Inc.